Bioretec (BRETEC) Investor presentation summary

Breakthrough technology and product pipeline

• First absorbable, osteopromotive magnesium implant approved in the US, with CE-marked trauma screw portfolio and FDA-approved LAG screw for foot and ankle.

• Clinically proven bone healing in 12 weeks, with full absorption by the body in 2-3 years.

• Strong pipeline includes DrillPins, Staples, Plates, IM-nails, and Spinal Cages, with significant launches planned through 2028.

• Clear commercial plan for full RemeOs product family rollout, leveraging regulatory authorizations.

Market opportunity and growth strategy

• Addressable market for the full product line exceeds $10B, with rapid adoption forecasted for absorbable implants.

• Trauma screw market alone projected to reach ~$1.2B by 2033, with RemeOs positioned to capture share from traditional metals.

• Commercialization underway in the US and Europe, supported by FDA and CE approvals and expanding distribution networks.

• Real-world clinical data from EU launches to support US expansion and broader product indications.

Operational and financial highlights

• Net sales more than doubled year-over-year in Q1 2025, rising 105% to EUR 1.4M.

• Sales margin slightly decreased to 66% due to higher share of lower-margin Asian sales.

• Highest quarterly manufacturing output achieved, with eight new US distributors signed in Q1 2025.

• EBITDA loss slightly increased, but EBITDA-% improved from (163%) to (89%).